Menu
 
Research menu
Jump to menu

Publications:  Prof Borislava Mihaylova

Mach F, Baigent C, Catapano AL, Koskina KC, Casula M, Badimon L, Chapman MJ, De Backer GG et al.(2019). 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis vol. 290, 140-205.
10.1016/j.atherosclerosis.2019.08.014
Keng MJ, Tsiachristas A, Leal J, Gray A, Mihaylova B(2019). Impact of achieving primary care targets in type 2 diabetes on health outcomes and healthcare costs. Diabetes, Obesity and Metabolism vol. 21, (11) 2405-2412.
10.1111/dom.13821
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58831
Levy M, Chen Y, Clarke R, Bennett D, Tan Y, Guo Y, Bian Z, Lv J et al. (2019). Declining socioeconomic inequalities in hospital care use and case fatality rates for stroke and ischaemic heart disease in China during 2009-16: a prospective study of 0.5 million adults. LANCET. vol. 394, 9-9.
Thorn J, Davies CF, Brookes ST, Dritsaki M, Gray E, Hughes D, Noble SM, Petrou S et al. (2019). Essential items for a Health Economics Analysis Plan (HEAP): expert Delphi consensus survey. TRIALS. vol. 20,
Oke JL, Feakins BG, Schlackow I, Mihaylova B, Simons C, O'Callaghan CA, Lasserson DS, Hobbs FDR et al.(2019). Statistical models for the deterioration of kidney function in a primary care population: A retrospective database analysis. F1000Research vol. 8, 1618-1618.
10.12688/f1000research.20229.1
Hopewell JC, Ibrahim M, Hill M, Shaw PM, Braunwald E, Blaustein RO, Bowman L, Landray MJ et al.(2019). Impact of ADCY9 Genotype on Response to Anacetrapib. Circulation
10.1161/CIRCULATIONAHA.119.041546
Schlackow I, Kent S, Herrington W, Emberson J, Haynes R, Reith C, Collins R, Landray MJ et al.(2019). Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney Int vol. 96, (1) 170-179.
10.1016/j.kint.2019.01.028
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58061
Schlackow I, Kent S, Herrington W, Emberson J, Haynes R, Reith C, Collins R, Landray M et al.(2019). Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International
10.1016/j.kint.2019.01.028
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58877
Edwards MR, Forbes G, MacDonald N, Berdunov V, Mihaylova B, Dias P, Thomson A, Grocott MP et al.(2019). Optimisation of Perioperative Cardiovascular Management to Improve Surgical Outcome II (OPTIMISE II) trial: study protocol for a multicentre international trial of cardiac output-guided fluid therapy with low-dose inotrope infusion compared with usual care in patients undergoing major elective gastrointestinal surgery. BMJ Open vol. 9, (1) e023455-e023455.
10.1136/bmjopen-2018-023455
https://qmro.qmul.ac.uk/xmlui/handle/123456789/56225
Keng MJ, Tsiachristas A, Leal J, Gray AM, Mihaylova B (2019). Impact of variation in Type 2 diabetes care on health outcomes and healthcare costs. DIABETIC MEDICINE. vol. 36, 161-161.
Kent S, Aveyard P, Astbury N, Mihaylova B, Jebb SA(2019). Is Doctor Referral to a Low-Energy Total Diet Replacement Program Cost-Effective for the Routine Treatment of Obesity?. Obesity vol. 27, (3) 391-398.
10.1002/oby.22407
https://qmro.qmul.ac.uk/xmlui/handle/123456789/56074
MIHAYLOVA BA(2019). Efficacy and safety of statin therapy in older people: meta-analysis of individual participant data from 28 randomised controlled trials. Lancet407-415.
10.1016/S0140-6736(18)31942-1
https://qmro.qmul.ac.uk/xmlui/handle/123456789/55109
Kent S, Jebb S, Gray A, Green J, REEVES G, Beral V, Cairns B, MIHAYLOVA B(2018). Body Mass Index and use and costs of primary care services among women aged 55 to 79 years in England: a cohort and linked data study. International Journal of Obesity
10.1038/s41366-018-0288-6
https://qmro.qmul.ac.uk/xmlui/handle/123456789/53466
Castellani J, Mihaylova B, Siribié M, Gansane Z, Ouedraogo AZ, Fouque F, Sirima SB, Evers SMAA et al.(2018). Household costs and time to treatment for children with severe febrile illness in rural Burkina Faso: The role of rectal artesunate 11 Medical and Health Sciences 1103 Clinical Sciences. Malaria Journal vol. 17, (1)
10.1186/s12936-018-2526-8
https://qmro.qmul.ac.uk/xmlui/handle/123456789/49863
Herrington WG, Donovan K, Mihaylova B(2018). Authors’ reply. Journal of the American Society of Nephrology vol. 29, (10) 2602-2603.
10.1681/ASN.2018060612
Mihaylova B, Collaborative HT-R (2018). Assessing cardiovascular risk in people with atherosclerotic vascular disease on intensive statin therapy. EUROPEAN HEART JOURNAL. vol. 39, 1054-1054.
Jepson M, Elliott D, Conefrey C, Wade J, Rooshenas L, Wilson C, Beard D, Blazeby JM et al.(2018). An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment. Journal of Clinical Epidemiology vol. 99, 75-83.
10.1016/j.jclinepi.2018.02.018
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58064
Marthi A, Donovan K, Haynes R, Wheeler DC, Baigent C, Rooney CM, Landray MJ, Moe SM et al.(2018). Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis. Journal of the American Society of Nephrology vol. 29, (7) 2000-2013.
10.1681/ASN.2017121334
https://qmro.qmul.ac.uk/xmlui/handle/123456789/49783
Lokuge K, de Waard DD, Halliday A, Gray A, Bulbulia R, Mihaylova B (2018). Meta-Analysis of the Procedural Risks of Carotid Endarterectomy and Carotid Artery Stenting Over Time. JOURNAL OF VASCULAR SURGERY. vol. 67, 1934-1935.
10.1016/j.jvs.2018.04.008
Morton RL, Schlackow I, Gray A, Emberson J, Herrington W, Staplin N, Reith C, Howard K et al.(2018). Impact of CKD on Household Income. Kidney International Reports vol. 3, (3) 610-618.
10.1016/j.ekir.2017.12.008
https://qmro.qmul.ac.uk/xmlui/handle/123456789/50063
Lokuge K, de Waard DD, Halliday A, Gray A, Bulbulia R, Mihaylova B(2018). Meta-analysis of the procedural risks of carotid endarterectomy and carotid artery stenting over time. British Journal of Surgery vol. 105, (1) 26-36.
10.1002/bjs.10717
https://qmro.qmul.ac.uk/xmlui/handle/123456789/40323
Schlackow I, Kent S, Herrington W, Emberson J, Haynes R, Reith C, Wanner C, Fellström B et al.(2017). A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease. Heart vol. 103, (23) 1880-1890.
10.1136/heartjnl-2016-310970
https://qmro.qmul.ac.uk/xmlui/handle/123456789/49503
Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP et al.(2017). Effects of anacetrapib in patients with atherosclerotic vascular disease. New England Journal of Medicine vol. 377, (13) 1217-1227.
10.1056/NEJMoa1706444
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58065
Kent S, Fusco F, Gray A, Jebb SA, Cairns BJ, Mihaylova B(2017). Body mass index and healthcare costs: a systematic literature review of individual participant data studies. Obesity Reviews vol. 18, (8) 869-879.
10.1111/obr.12560
https://qmro.qmul.ac.uk/xmlui/handle/123456789/49483
Clayton GL, Smith IL, Higgins JPT, Mihaylova B, Thorpe B, Cicero R, Lokuge K, Forman JR et al.(2017). The INVEST project: Investigating the use of evidence synthesis in the design and analysis of clinical trials. Trials vol. 18, (1)
10.1186/s13063-017-1955-y
https://qmro.qmul.ac.uk/xmlui/handle/123456789/42303
Schlackow I, Mihaylova B, Grp SHARPC (2017). A lifetime disease model based on an RCT: development, validation and applications. TRIALS. vol. 18,
Thorn J, Ridyard C, Hughes D, Wordsworth S, Mihaylova B, Noble SM, Hollingworth W (2017). Health economics analysis plans: the current state of play. TRIALS. vol. 18,
Schlackow I, Gray A, Sharples L, Jackson C, Welton N, Mihaylova B (2017). Methods for extrapolation from clinical trial data to inform economic evaluations: a taxonomy. TRIALS. vol. 18,
de Waard DD, Halliday A, de Borst GJ, Bulbulia R, Huibers A, Casana R, Bonati LH, Tolva V et al.(2017). Choices of Stent and Cerebral Protection in the Ongoing ACST-2 Trial: A Descriptive Study. Eur J Vasc Endovasc Surg vol. 53, (5) 617-625.
10.1016/j.ejvs.2016.12.034
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58058
Kent S, Green J, Reeves G, Beral V, Gray A, Jebb SA, Cairns BJ, Mihaylova B et al.(2017). Hospital costs in relation to body-mass index in 1·1 million women in England: a prospective cohort study. The Lancet Public Health vol. 2, (5) e214-e222.
10.1016/S2468-2667(17)30062-2
https://qmro.qmul.ac.uk/xmlui/handle/123456789/49626
Bowman L, Chen F, Sammons E, Hopewell JC, Wallendszus K, Stevens W, Valdes-Marquez E, Wiviott S et al.(2017). Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics. American Heart Journal vol. 187, 182-190.
10.1016/j.ahj.2017.02.021
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58063
Achelrod D, Gray A, Preiss D, Mihaylova B(2017). Cholesterol- and blood-pressure-lowering drug use for secondary cardiovascular prevention in 2004-2013 Europe. European Journal of Preventive Cardiology vol. 24, (4) 426-436.
10.1177/2047487316676906
https://qmro.qmul.ac.uk/xmlui/handle/123456789/50384
Herrington WG, Emberson J, Mihaylova B, Collins R, Baigent C(2016). Are statins useful in patients with advanced chronic kidney disease? – Authors' reply. The Lancet Diabetes and Endocrinology vol. 4, (12) 971-972.
10.1016/S2213-8587(16)30266-2
https://qmro.qmul.ac.uk/xmlui/handle/123456789/50943
Thorn JC, Ridyard CH, Hughes D, Wordsworth S, Mihaylova B, Noble S, Hollingworth W (2016). HEALTH ECONOMICS ANALYSIS PLANS: WHERE ARE WE NOW?. VALUE IN HEALTH. vol. 19, A397-A397.
10.1016/j.jval.2016.09.291
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58062
Lokuge K, de Waard D, Bulbulia R, Gray A, Halliday A, Mihaylova B (2016). Procedural risks of carotid endarterectomy and carotid artery stenting have improved since 2005: Results from a systematic review of observational studies. INTERNATIONAL JOURNAL OF STROKE. vol. 11, S25-S25.
Herrington WG, Emberson J, Mihaylova B, Blackwell L, Reith C, Solbu MD, Mark PB, Fellström B et al.(2016). Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. The Lancet Diabetes and Endocrinology vol. 4, (10) 829-839.
10.1016/S2213-8587(16)30156-5
https://qmro.qmul.ac.uk/xmlui/handle/123456789/50603
Kent S, Haynes R, Hopewell JC, Parish S, Gray A, Landray MJ, Collins R, Armitage J et al.(2016). Effects of vascular and nonvascular adverse events and of extended-release niacin with laropiprant on health and healthcare costs. Circulation: Cardiovascular Quality and Outcomes vol. 9, (4) 348-354.
10.1161/CIRCOUTCOMES.115.002592
https://qmro.qmul.ac.uk/xmlui/handle/123456789/51205
Reith C, Blackwell L, Emberson J, Mihaylova B, Armitage J, Fulcher J, Keech A, Simes J et al.(2016). Protocol for analyses of adverse event data from randomized controlled trials of statin therapy. American Heart Journal vol. 176, 63-69.
10.1016/j.ahj.2016.01.016
Mihaylova B, Schlackow I, Herrington W, Lozano-Kühne J, Kent S, Emberson J, Reith C, Haynes R et al.(2016). Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in CKD: Results of the study of heart and renal protection (SHARP). American Journal of Kidney Diseases vol. 67, (4) 576-584.
10.1053/j.ajkd.2015.09.020
Morton RL, Schlackow I, Staplin N, Gray A, Cass A, Haynes R, Emberson J, Herrington W et al.(2016). Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD. American Journal of Kidney Diseases vol. 67, (1) 31-39.
10.1053/j.ajkd.2015.07.021
Castellani J, Nsungwa-Sabiiti J, Mihaylova B, Ajayi IO, Siribié M, Afonne C, Balyeku A, Sermé L et al.(2016). Impact of improving community-based access to malaria diagnosis and treatment on household costs. Clinical Infectious Diseases vol. 63, S256-S263.
10.1093/cid/ciw623
https://qmro.qmul.ac.uk/xmlui/handle/123456789/39443
Castellani J, Mihaylova B, Ajayi IO, Siribié M, Nsungwa-Sabiiti J, Afonne C, Sermé L, Balyeku A et al.(2016). Quantifying and valuing community healthworker time in improving access to malaria diagnosis and treatment. Clinical Infectious Diseases vol. 63, S298-S305.
10.1093/cid/ciw629
https://qmro.qmul.ac.uk/xmlui/handle/123456789/50543
Morton RL, Schlackow I, Mihaylova B, Staplin ND, Gray A, Cass A(2016). The impact of social disadvantage in moderate-to-severe chronic kidney disease: An equity-focused systematic review. Nephrology Dialysis Transplantation vol. 31, (1) 46-56.
10.1093/ndt/gfu394
Lokuge K, Halliday A, Bulbulia R, Gray A, Mihaylova B (2015). Systematic review of randomised and observational evidence of effects of treatments of carotid stenosis to prevent stroke. TRIALS. vol. 16,
10.1186/1745-6215-16-S2-P164
Castellani J, Mihaylova B, Evers SMAA, Paulus ATG, Mrango ZE, Kimbute O, Staff PLOSO(2015). Out-of-Pocket Costs and Other Determinants of Access to Healthcare for Children with Febrile Illnesses: A Case-Control Study in Rural Tanzania (vol 10, 0122386, 2015). PLOS ONE vol. 10, (5) Article ARTN e0128166,
10.1371/journal.pone.0128166
Morton RL, Schlackow I, Staplin N, Gray A, Cass A, Haynes R, Emberson J, Herrington W et al. (2015). IMPACT OF EDUCATIONAL ATTAINMENT ON HEALTH OUTCOMES IN MODERATE-TO-SEVERE CHRONIC KIDNEY DISEASE. NEPHROLOGY DIALYSIS TRANSPLANTATION. vol. 30,
10.1093/ndt/gfv175.11
Kent S, Schlackow I, Lozano-Kühne J, Reith C, Emberson J, Haynes R, Gray A, Cass A et al.(2015). What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?. BMC Nephrology vol. 16, (1)
10.1186/s12882-015-0054-0
Castellani J, Mihaylova B, Evers SMAA, Paulus ATG, Mrango ZE, Kimbute O, Shishira JP, Mulokozi F et al.(2015). Out-of-pocket costs and other determinants of access to healthcare for children with febrile illnesses: A case-control study in rural Tanzania. PLoS ONE vol. 10, (4)
10.1371/journal.pone.0122386
Alva ML, Gray A, Mihaylova B, Leal J, Holman RR(2015). The impact of diabetes-related complications on healthcare costs: New results from the UKPDS (UKPDS 84). Diabetic Medicine vol. 32, (4) 459-466.
10.1111/dme.12647
Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R et al.(2015). Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174 000 participants in 27 randomised trials. The Lancet vol. 385, (9976) 1397-1405.
10.1016/S0140-6736(14)61368-4
Lokuge K, Halliday A, Bulbulia R, Gray A, Mihaylova B(2015). Systematic review of randomised and observational evidence of effects of treatments of carotid stenosis to prevent stroke. Trials vol. 16, (Suppl 2) P164-P164.
10.1186/1745-6215-16-S2-P164
Alva M, Gray A, Mihaylova B, Clarke P(2014). The effect of diabetes complications on health-related quality of life: The importance of longitudinal data to address patient heterogeneity. Health Economics (United Kingdom) vol. 23, (4) 487-500.
10.1002/hec.2930
Schlackow I, Mihaylova B(2013). Developing a lifetime disease model from RCT data using parametric models with time-updated covariates. Trials vol. 14, (Suppl 1) O24-O24.
10.1186/1745-6215-14-S1-O24
Halliday A, Bulbulia R, Gray W, Naughten A, Den Hartog A, Delmestri A, Wallis C, Le Conte S et al.(2013). Status update and interim results from the asymptomatic carotid surgery trial-2 (ACST-2). European Journal of Vascular and Endovascular Surgery vol. 46, (5) 510-518.
10.1016/j.ejvs.2013.07.020
Mihaylova B, Emberson J, Keech A, Collins R, Baigent C(2012). Authors' reply. The Lancet vol. 380, (9856) 1817-1818.
10.1016/S0140-6736(12)62027-3
Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A et al.(2012). The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. The Lancet vol. 380, (9841) 581-590.
10.1016/S0140-6736(12)60367-5
Mihaylova B, Briggs A, O'Hagan A, Thompson SG(2011). Review of statistical methods for analysing healthcare resources and costs. Health Economics vol. 20, (8) 897-916.
10.1002/hec.1653
Alva M, Gray AM, Mihaylova B, Holman RR (2011). Outpatient Resource Utilization of Type-2 Diabetes Patients: New Evidence from the UKPDS. DIABETES. vol. 60, A67-A67.
Alva ML, Gray A, Mihaylova B, Clarke P(2011). The effect of diabetes complications on health-related quality of life: estimating the bias due to unobserved heterogeneity using the UKPDS. Trials vol. 12, (Suppl 1) A64-A64.
10.1186/1745-6215-12-S1-A64
Buchanan J, Mihaylova B, Gray A, White N(2010). Cost-effectiveness of pre-referral antimalarial, antibacterial, and combined rectal formulations for severe febrile illness. PLoS ONE vol. 5, (12)
10.1371/journal.pone.0014446
Maude RJ, Mihaylova B, Warsame M, Singlovic J, Pongtavornpinyo W, Saralamba S, Dondorp AM, White NJ et al. (2010). RECTAL AND INTRAVENOUS ARTESUNATE FOR SEVERE MALARIA: MODELLING THE IMPACT OF ARTEMISININ RESISTANCE. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE. vol. 83, 377-377.
Alva ML, Gray A, Mihaylova B, Clarke P (2010). Estimating the quality of life impact of diabetes related complications: new results from the UKPDS. DIABETOLOGIA. vol. 53, S52-S52.
Mihaylova B, Pitman R, Tincello D, Van Der Vaart H, Tunn R, Timlin L, Quail D, Johns A et al.(2010). Cost-effectiveness of duloxetine: The stress urinary incontinence treatment (SUIT) study. Value in Health vol. 13, (5) 565-572.
10.1111/j.1524-4733.2010.00729.x
Mihaylova B, Briggs A, Hlatky M, Armitage J, Parish S, Gray A, Collins R, Collins R et al.(2009). Statin cost-effectiveness in the United States for people at different vascular risk levels. Circulation: Cardiovascular Quality and Outcomes vol. 2, (2) 65-72.
10.1161/CIRCOUTCOMES.108.808469
Briggs A, Mihaylova B, Sculpher M, Hall A, Wolstenholme J, Simoons M, Deckers J, Ferrari R et al.(2007). Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart vol. 93, (9) 1081-1086.
10.1136/hrt.2005.086728
Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R(2006). Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from randomised trial of 20 536 people. British Medical Journal vol. 333, (7579) 1145-1148.
10.1136/bmj.38993.731725.BE
Briggs A, Mihaylova B, Sculpher M, Hall A, Wolstenholme J, Simoons M, Ferrari R, Remme W et al. (2006). The cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. HEART. vol. 92, A36-A36.
Briggs A, Mihaylova B, Sculpher M, Hall A, Wolstenholme J, Simoons M, Ferrari R, Remme WJ et al. (2006). The cost-effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. vol. 47, 260A-260A.
Mihaylova B, Armitage J, Briggs A, Gray A, Parish S, Collins R, Collaborati HPS (2005). Economic analysis of simvastatin in 20,536 people at different levels of vascular disease risk based on US costs: Randomised placebo-controlled trial. CIRCULATION. vol. 112, U900-U901.
Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R, Collins R, Meade T et al.(2005). Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: Economic analysis of a randomised trial in 20 536 individuals. Lancet vol. 365, (9473) 1779-1785.
10.1016/S0140-6736(05)63014-0
Briggs A, Armitage J, Gray A, Mihaylova B, Parish S, Young A, Collins R, Collaborati HPS (2003). Economic evaluation of the Heart Protection Study. CIRCULATION. vol. 108, 776-776.
Bryant J, Loveman E, Chase D, Mihaylova B, Cave C, Gerard K, Milne R(2002). Clinical effectiveness and cost-effectiveness of growth hormone in adults in relation to impact on quality of life: A systematic review and economic evaluation. Health Technology Assessment vol. 6, (19)
Bryant J, Cave C, Mihaylova B, Chase D, McIntyre L, Gerard K, Milne R(2002). Clinical effectiveness and cost-effectiveness of growth hormone in children: A systematic review and economic evaluation. Health Technology Assessment vol. 6, (18)
10.3310/hta6180
Return to top